All Clinical Trials

A listing of 23116 clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Trials

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

Featured Trial

Healthy Participants Needed (Colonoscopy + Cancer Screening)

Recruiting

Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.

Conditions:

Healthy

Healthy Volunteers

Healthy Subjects

Healthy Volunteer

Healthy Participants

Learn More

Featured Therapy

Unique Treatment for High Blood Pressure

Worried about high blood pressure? Think beyond typical high blood pressure treatments.

People who may be candidates for this procedure:

• Are at least 18 years old
• Have been unable to manage their high blood pressure with medications or lifestyle changes alone¹

Learn about a safe and effective procedure that may help reduce high blood pressure. See if you qualify today.

¹ Kandzari DE, et al. J Am Coll Cardiol. Nov 7, 2023;82(19):1809-1823.

Conditions:

High Blood Pressure

High Blood Pressure (& [Essential Hypertension])

High Blood Pressure (Hypertension).

Hypertension

Essential Hypertension

Learn More

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

Featured Trial

Discover Clinical Trials In Your Area (Compensation Provided)

Recruiting

Clinical trials in your area are actively enrolling — and they compensate you for your time. Finding the right one has never been easier.

- Matched to trials in your zip code
- Compensation for time & travel
- Free or low-cost treatments available
- No experience or medical background needed
- Takes just 30 seconds to see if you qualify

Conditions:

Healthy

Healthy Volunteers

Learn More

Featured Offer

Lose 20% of Body Weight With GLP-1's

Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to tirzepatide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

Semaglutide and Tirzepatide are advanced GLP-1 medications designed to support weight management and metabolic health. They work by targeting GLP-1 receptors in the body, helping regulate appetite, improve blood sugar control, and support sustainable weight loss (up to 22% of body weight).

Get $50 off your first order using promo code: policy-lab-50

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

Featured Trial

COVID-19 Vaccine Clinical Trial (Compensation Provided)

Recruiting

Healthy adults ages 50-64 may qualify. You may be eligible if you haven’t received a COVID-19 vaccine and haven’t had COVID-19 in the last 90 days.

Qualified participants may receive compensation for time and travel.

Conditions:

Healthy

Vaccine

COVID19

COVID-19

COVID-19 Vaccine

Learn More

Radiation Free Study

NCT06549348

Recruiting

This is a prospective, randomized, unblinded, multi-center study. Sites were selected from different geographies (EU and US) with different clinical practice to ensure the results are more generalizable. Primary objective is to demonstrate that the average procedure fluoroscopy time using LumiGuide is lower compared to conventional fluoroscopy guidance in Fenestrated Endovascular Aortic Repair (FEVAR)

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/29/2025

Locations: University of Alabama, Birmingham, Alabama +8 locations

Conditions: Aortic Aneurysm

Learn More ›

To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications

NCT06553027

Recruiting

This is a randomized, double-blind, placebo-controlled, multicenter study in participants with Parkinson's disease (PD) with motor fluctuations. Participants will be randomized to receive once-daily oral doses of either 75 milligrams (mg) CVN424 or 150 mg CVN424, or a matching placebo for 12 weeks. Participants who successfully complete this study and retain eligibility/suitability will be invited to participate in a future open-label extension (OLE) study.

Gender:

ALL

Ages:

30 years and above

Trial Updated:

07/29/2025

Locations: The Kirklin Clinic of UAB Hospital, Birmingham, Alabama +37 locations

The Kirklin Clinic of UAB Hospital, Birmingham, Alabama

University of Alabama at Birmingham, Birmingham, Alabama

Parkinson's Research Centers of America - Palo Alto, Palo Alto, California

CenExel Rocky Mountain Clinical Research, Englewood, Colorado

Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida

SFM Clinical Research, LLC, Boca Raton, Florida

K2 Medical Research, Maitland, Florida

Renstar Medical Research, Ocala, Florida

N1 Research LLc, Orlando, Florida

Parkinson's Disease Center of SWFL, Port Charlotte, Florida

University Clinical Research-DeLand, LLC d/b/a Accel Research Sites - Brain & Spine Institute, Port Orange, Florida

University of Kansas Medical Center, Kansas City, Kansas

University of Kentucky, Dept of Neurology Kentucky Neuroscience Institute Research, Lexington, Kentucky

Boston Clinical Trials, Boston, Massachusetts

University of Michigan Dept. of Neurology, Ann Arbor, Michigan

University of Michigan Hospital - Michigan Clinical Research Unit (MCRU), Ann Arbor, Michigan

Quest Research Institute, Farmington Hills, Michigan

Boro Neurology, Hopewell, New Jersey

Parkinson's Research Centers of America - Long Island, Commack, New York

Weill Cornell Medical College, New York, New York

Duke Neurology Morreene Road Clinic, Durham, North Carolina

Raleigh Neurology Associates, Raleigh, North Carolina

Velocity Clinical Research, Raleigh, North Carolina

Riverhills Healthcare, Inc dba Riverhills Neuroscience, Cincinnati, Ohio

The Ohio State University Wexner Medical Center, Columbus, Ohio

The Ohio State University - Martha Morehouse Medical Plaza, Columbus, Ohio

The Movement Disorder Clinic of Oklahoma, Tulsa, Oklahoma

Veracity Neuroscience LLC, Memphis, Tennessee

Horizon Clinical Research Group, Cypress, Texas

Texas Movement Disorder Specialists, PLLC, Georgetown, Texas

Houston Methodist Neurological Institute, Houston, Texas

Gill Neuroscience, Houston, Texas

Central Texas Neurology Consultants, Round Rock, Texas

Inova Neurology - Fairfax, Fairfax, Virginia

Inova Fairfax Medical Campus, Falls Church, Virginia

Henrico Doctors Neurology Associates, LLC, Richmond, Virginia

Inland Northwest Research, Spokane, Washington

Medical College of Wisconsin-Department of Neurology, Milwaukee, Wisconsin

Conditions: Parkinson Disease

Learn More ›

Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery (SRS) in Patients With Primary and Secondary Central Nervous System Lymphomas (SOLAR)

NCT06607549

Recruiting

The purpose of this clinical trial is to learn if drugs loncastuximab tesirine and rituximab (lonca-R) after stereotactic radiosurgery are safe and effective for treatment of central nervous system lymphomas.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/29/2025

Locations: Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah

Conditions: Central Nervous System Lymphoma

Learn More ›

Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

NCT06608927

Recruiting

The purpose of this study is to compare overall survival of quemliclustat, nab-paclitaxel and gemcitabine versus placebo, nab-paclitaxel and gemcitabine in all randomized patients.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/29/2025

Locations: Mayo Clinic Arizona - Phoenix Campus, Phoenix, Arizona +132 locations

Mayo Clinic Arizona - Phoenix Campus, Phoenix, Arizona

University of Arizona Cancer Center, Tucson, Arizona

University of California San Diego Health, La Jolla, California

Cancer & Blood Specialty Clinic - Los Alamitos, Los Alamitos, California

Keck Medicine of USC - Keck Hospital of USC, Los Angeles, California

Sutter Medical Center, Roseville, California

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California

UCLA Health - Santa Monica Cancer Care, Santa Monica, California

UCHealth Cancer Care - Anschutz Medical Campus - University of Colorado Cancer Center, Aurora, Colorado

USOR - Rocky Mountain Cancer Centers - Denver - Midtown, Denver, Colorado

Yale Cancer Center, New Haven, Connecticut

Mayo Clinic - Jacksonville, Jacksonville, Florida

Miami Cancer Institute, Miami, Florida

Piedmont Cancer Institute, Atlanta, Georgia

Emory University Hospital, Atlanta, Georgia

USOR - Illinois Cancer Specialists - Arlington Heights, Arlington Heights, Illinois

Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois

University of Chicago, Chicago, Illinois

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana

Cancer Center of Kansas - Medical Arts Tower, Wichita, Kansas

Mary Bird Perkins Cancer Center - Baton Rouge, Baton Rouge, Louisiana

Maine Medical Center, Portland, Maine

University of Michigan Rogel Cancer Center, Ann Arbor, Michigan

Cancer & Hematology Centers of Western Michigan - Lemmen-Holton Cancer Pavilion, Grand Rapids, Michigan

HealthPartners Cancer Research Center - Cancer Center at Regions Hospital, Minneapolis, Minnesota

Mayo Clinic - Rochester, Rochester, Minnesota

MediSync Clinical Research - Hattiesburg Clinic, Hattiesburg, Mississippi

Saint Luke's Hospital of Kansas City, Kansas City, Missouri

University of Nebraska Medical Center, Omaha, Nebraska

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey

University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico

Roswell Park Comprehensive Cancer Center, Buffalo, New York

Clinical Research Alliance, New Hyde Park, New York

New York University Medical Oncology Associates, New York, New York

Columbia University Irving Medical Center - Herbert Irving Pavilion, New York, New York

Memorial Sloan-Kettering Cancer Center - New York - Rockefeller Outpatient Pavilion, New York, New York

Mount Sinai Medical Center Comprehensive Cancer Center, New York, New York

James P. Wilmot Cancer Center, Rochester, New York

University Hospitals Cleveland Medical Center, Cleveland, Ohio

Stephenson Cancer Center, Oklahoma City, Oklahoma

Fox Chase Cancer Center, Philadelphia, Pennsylvania

University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, Pittsburgh, Pennsylvania

SCRI Oncology Partners, Nashville, Tennessee

Vanderbilt University Medical Center, Nashville, Tennessee

USOR - Texas Oncology - Austin Midtown, Austin, Texas

USOR - Texas Oncology - Dallas Fort Worth (DFW) - Baylor Charles A. Sammons Cancer Center, Dallas, Texas

University of Texas Southwestern Medical Center, Dallas, Texas

University of Texas MD Anderson Cancer Center, Houston, Texas

USOR - Texas Oncology - San Antonio Medical Center, San Antonio, Texas

USOR - Texas Oncology - Deke Slayton Cancer Center, Webster, Texas

Inova Medical Group - Hematology Oncology - Arlington, Fairfax, Virginia

Virginia Mason Medical Center, Seattle, Washington

Summit Cancer Centers - Spokane Valley, Spokane, Washington

USOR - Northwest Cancer Specialists, P.C. dba Compass Oncology - Vancouver Cancer Center, Vancouver, Washington

University of Wisconsin - Madison, Madison, Wisconsin

Chris O'Brien Lifehouse, Camperdown, Not set

Monash Health, Clayton, Not set

Oncology West - Murdoch, Murdoch, Not set

Wollongong Hospital, Wollongong, Not set

Salzburg Cancer Research Institute, Salzburg, Not set

Universitätsklinikum Sankt Pölten, Sankt Pölten, Not set

Krankenhaus Der Barmherzigen Brüder Wien, Wien, Not set

Medizinische Universität Wien, Wien, Not set

Institut Jules Bordet, Anderlecht, Not set

Imeldaziekenhuis, Bonheiden, Not set

Algemeen Ziekenhuis Groeninge - Campus Kennedylaan, Kortrijk, Not set

Ottawa Hospital - General Campus, Ottawa, Not set

Hôtel-Dieu de Sherbrooke, Sherbrooke, Not set

Princess Margaret Cancer Centre, Toronto, Not set

Sunnybrook Health Sciences Centre - Bayview Campus, Toronto, Not set

Nemocnice AGEL Nový Jičín a.s., Nový Jičín, Not set

Fakultni nemocnice v Motole, Praha, Not set

Centre Georges François Leclerc, Dijon cedex, Not set

Hôpital Huriez, Lille Cedex, Not set

Centre Léon Bérard, Lyon, Not set

Centre Hospitalier Universitaire de Poitiers, Poitiers, Not set

Gustave Roussy, Villejuif, Not set

Katholisches Klinikum Bochum - St. Josef-Hospital, Bochum, Not set

Universitatsklinikum Carl Gustav Carus Dresden, Dresden, Not set

Universitätsklinikum Düsseldorf, Düsseldorf, Not set

Krankenhaus Nordwest, Frankfurt am Main, Not set

Asklepios Klinik Altona, Hamburg, Not set

Facharztzentrum Eppendorf, Hamburg, Not set

Katholisches Marienkrankenhaus, Hamburg, Not set

Medizinische Hochschule Hannover, Hannover, Not set

SLK-Kliniken Heilbronn - Klinikum am Gesundbrunnen, Heilbronn, Not set

Elblandklinikum Riesa, Riesa, Not set

Universitätsklinikum Ulm, Ulm, Not set

Universitätsklinikum Würzburg, Wuerzburg, Not set

Azienda Ospedaliero-Universitaria di Bologna - Policlinico Sant Orsola-Malpighi, Bologna, Not set

Ospedale di Cremona, Cremona, Not set

Azienda Ospedaliero - Universitaria Careggi, Firenze, Not set

Fondazione IRCCS - Istituto Nazionale dei Tumori, Milano, Not set

Istituto Europeo di Oncologia, Milano, Not set

Azienda Ospedaliero - Universitaria di Modena, Modena, Not set

Istituto Oncologico Veneto - IRCCS, Padova, Not set

Ospedale Guglielmo da Saliceto, Piacenza, Not set

IRCCS Istituto Nazionale Tumori Regina Elena, Roma, Not set

Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Istituto Clinico Humanitas, Rozzano, Not set

Azienda Ospedaliero Universitaria Delle Marche, Torrette, Not set

Azienda Ospedaliera Universitaria Integrata Verona, Verona, Not set

National Cancer Center Hospital East, Kashiwa-shi, Not set

Cancer Institute Hospital of JFCR, Koto, Not set

Osaka Prefectural Hospital Organization - Osaka International Cancer Institute, Osaka, Not set

National Cancer Center Hospital, Tokyo, Not set

Toyama University Hospital, Toyama, Not set

Yamaguchi University Hospital, Ube, Not set

Kanagawa Cancer Center, Yokohama-Shi, Not set

Chonnam National University Hwasun Hospital, Hwasun, Not set

Cha Bundang Medical Center, Seongnam, Not set

Asan Medical Center, Seoul, Not set

Samsung Medical Center, Seoul, Not set

Seoul National University Hospital, Seoul, Not set

Severance Hospital, Seoul, Not set

Hospital Clinic de Barcelona, Barcelona, Not set

Hospital Universitari Vall d'Hebrón, Barcelona, Not set

Hospital General Universitario de Elche, Elche, Not set

Institut Català d'Oncologia Girona (ICO Girona), Girona, Not set

Clínica Universidad de Navarra - Madrid, Madrid, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

Hospital Universitario HM Sanchinarro, Madrid, Not set

Hospital Universitario La Paz, Madrid, Not set

Clinica Universidad de Navarra - Pamplona, Pamplona, Not set

Hospital Universitario de Navarra, Pamplona, Not set

Consorci Hospital General Universitari de València, Valencia, Not set

Hospital Alvaro Cunqueiro - Clinico Universitario Vigo, Vigo, Not set

Hospital Universitario Miguel Servet, Zaragoza, Not set

Hull University Teaching Hospitals NHS Trust, Cottingham, Not set

Royal Free London NHS Foundation Trust, London, Not set

Sarah Cannon Research Institute London, London, Not set

University College London Hospitals NHS Foundation Trust, London, Not set

The Christie NHS Foundation Trust, Manchester, Not set

University Hospitals Birmingham NHS Foundation Trust, Oxford, Not set

Conditions: Metastatic Pancreatic Ductal Adenocarcinoma

Learn More ›

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

NCT06618287

Recruiting

The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/29/2025

Locations: Local Institution - 0066, Birmingham, Alabama +46 locations

Local Institution - 0066, Birmingham, Alabama

University of Miami Hospital and Clinics, Sylvester Cancer Center, Miami, Florida

Local Institution - 0065, Iowa City, Iowa

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey

Cleveland Clinic, Cleveland, Ohio

Local Institution - 0052, Portland, Oregon

Local Institution - 0014, Pittsburgh, Pennsylvania

Swedish Medical Center, Seattle, Washington

Liverpool Hospital, Liverpool, New South Wales

Princess Alexandra Hospital, Woolloongabba, Queensland

Cross Cancer Institute, Edmonton, Alberta

Local Institution - 0064, Newmarket, Ontario

Local Institution - 0023, Ottawa, Ontario

The Ottawa Hospital - General Campus, Ottawa, Ontario

Jewish General Hospital, Montreal, Quebec

Centre Hospitalier de l'Université de Montréal, Montréal, Quebec

Local Institution - 0048, Santiago, Región Metropolitana De Santiago

Local Institution - 0049, Santiago, Región Metropolitana De Santiago

Local Institution - 0047, Santiago, Región Metropolitana De Santiago

Local Institution - 0043, Bordeaux, Aquitaine

Local Institution - 0045, Marseille, Bouches-du-Rhône

Local Institution - 0053, Montpellier, Hérault

Local Institution - 0050, Lyon, Rhône-Alpes

Local Institution - 0041, Villejuif, Val-de-Marne

Local Institution - 0054, Paris, Not set

Local Institution - 0040, Paris, Not set

Local Institution - 0034, Aviano, Friuli-Venezia Giulia

Local Institution - 0033, Milan, Lombardia

Local Institution - 0056, Candiolo, Torino

Local Institution - 0035, Firenze, Toscana

Local Institution - 0032, Roma, Not set

Leids Universitair Medisch Centrum, Leiden, Zuid-Holland

Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI AVL), Amsterdam, Not set

Local Institution - 0062, Santiago de Compostela, A Coruña [La Coruña]

Hospital Universitari Vall d'Hebron, Barcelona, Barcelona [Barcelona]

Local Institution - 0058, Hospitalet, Barcelona [Barcelona]

Local Institution - 0059, Barcelona, Catalunya [Cataluña]

Hospital Universitario 12 de Octubre, Madrid, Madrid, Comunidad De

Local Institution - 0061, Majadahonda, Madrid, Comunidad De

Hospital Universitario Fundación Jiménez Díaz, Madrid, Not set

Hospital Universitario HM Sanchinarro, Madrid, Not set

Local Institution - 0063, Málaga, Not set

Local Institution - 0060, València, Not set

Royal Free Hospital, London, England

Local Institution - 0021, Glasgow, Glasgow City

University Hospitals Birmingham NHS Foundation Trust, Birmingham, West Midlands

Local Institution - 0001, Newcastle upon Tyne, Not set

Conditions: Lung Cancer

Learn More ›

A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer

NCT06623396

Recruiting

Participants will have a sample of their white blood cells, called T cells, collected using a procedure called leukapheresis. The collected T cells will be sent to a laboratory at Memorial Sloan Kettering to be changed (modified) to become MSLN-targeted CAR T cells, the CAR T-cell therapy that participants will receive during the study. Participant study therapy will take about 3-4 weeks.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/29/2025

Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey +6 locations

Conditions: Mesothelin Positive, Mesothelin-Expressing Tumors, Esophageal Adenocarcinoma, Esophageal Adenocarcinomas, Esophagogastric Adenocarcinoma, Peritoneal Carcinomatosis, Breast Neoplasms, Diabetes Mellitus

Learn More ›

A Mobile Intervention to Reduce Pain and Improve Health-III

NCT06623669

Recruiting

The experience of chronic pain powerfully and negatively affects quality of life and functional independence in aging. Unfortunately, while as many as three in four older adults experience chronic pain, few have access to effective non-pharmacological pain management strategies. Participating in regular physical activity, avoiding sustained sitting, and maintaining a healthy weight are important and interrelated lifestyle inputs to chronic pain, and socially rich behavioral interventions informed by contemporary theories of behavior change appear important for engaging in activity and healthy eating in the long term. Our group has demonstrated in a series of Stage I trials that a group-mediated behavioral intervention combining dietary behavior change and a physical activity program focused on moving often throughout the day contributes to meaningful weight loss, and lasting weight maintenance, with pilot data suggesting this may contribute to improved pain, physical function, and health-related quality of life among older adults with chronic pain. As these were NIH Stage I trials, there are several important gaps to be addressed in the present trial: (1) both studies of chronic pain recruited small samples and were 12 weeks in duration, limiting our ability to establish efficacy and the durability of changes to activity, HRQOL, and pain outcomes; (2) participants included anyone with chronic pain, regardless of pain type, a likely contributor to heterogeneous pain intensity and interference findings; and (3) the investigators have yet to examine behavioral maintenance. The overarching goal of the proposed Stage II "mobile intervention to reduce pain and improve health-III (MORPH-III)" is to establish the efficacy of the intervention for enhancing physical activity via steps (primary), and for reducing pain interference and body weight while enhancing physical function (secondary) among older adults with chronic knee or hip osteoarthritic (OA) pain. The investigators will recruit 200 older adults with knee or hip osteoarthritic pain to engage in a 6-month remotely delivered intervention comprising weekly group or individual intervention meetings plus brief individual goal-setting coaching calls. This will be followed by a 12-month no-contact maintenance period, where participants will attempt to sustain behavioral goals on their own. The Specific Aims are: Specific Aim 1: To examine the impact of MORPH on ActivPAL-assessed daily steps relative to an enhanced usual care control. Hypotheses: MORPH will significantly increase steps relative to control at month 6. Specific Aim 2: To examine the impact of MORPH on pain interference, change in body weight, and physical function relative to the enhanced usual care control. Hypotheses: MORPH will result in significant reductions in pain interference and body weight and improvement in physical function relative to control at month 6. Exploratory Aims: Aim 1: To investigate the impact of the MORPH intervention on steps, weight change, pain interference, and physical function at month 18. Aim 2: If the MORPH intervention results in reduced pain interference at 6 and/or 18 months, the investigators will examine the extent to which 6-month change in steps, weight, pain self-efficacy, and catastrophizing mediate change in interference at 6 and/or 18 months. Read Less

Gender:

ALL

Ages:

65 years and above

Trial Updated:

07/29/2025

Locations: Wake Forest University, Winston Salem, North Carolina

Conditions: Chronic Pain, Osteoarthritis, Obesity and Overweight, Inactivity

Learn More ›

64Cu-LLP2A for Imaging Hematologic Malignancies

NCT06636175

Recruiting

This phase of the protocol (protocol part B), seeks to evaluate the new formulation in healthy normal volunteers to confirm the new formulation provides comparable human dosimetry to which was seen and published in protocol part A. Additionally, the new formulation will be studied utilizing an expanded patient population to include patients with confirmed diagnosis of multiple myeloma (MM), low-grade lymphoma, or MM and lymphoma patients who are status post bone marrow transplant (BMT) with nega... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/29/2025

Locations: Washington University School of Medicine, Saint Louis, Missouri

Conditions: Multiple Myeloma, Low-Grade Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Lymphoplasmacytic Lymphoma, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia

Learn More ›

Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users

NCT06659029

Recruiting

PRIMULA Preg (Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users) is a prospective, observational cohort study designed to evaluate the association between anifrolumab exposure during pregnancy and subsequent adverse maternal, fetal, and infant outcomes. This study will fulfil an FDA post-marketing requirement.

Gender:

FEMALE

Ages:

All

Trial Updated:

07/29/2025

Locations: Research Site, Las Vegas, Nevada

Conditions: Systemic Lupus Erythematosus

Learn More ›

CT-95 in Advanced Cancers Associated With Mesothelin Expression

NCT06756035

Recruiting

This is a Phase 1a/1b open-label, dose escalation study to evaluate the safety and efficacy of CT-95 (study drug), a humanized T cell engaging bispecific antibody targeting Mesothelin, in subjects with advanced solid tumors associated with Mesothelin expression.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/29/2025

Locations: Context Investigational Site, Denver, Colorado +7 locations

Conditions: Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer, Malignant Pleural Mesothelioma, Advanced, Malignant Peritoneal Mesothelioma, Advanced, Pancreatic Adenocarcinoma Advanced or Metastatic, Lung Adenocarcinoma Metastatic, Cholangiocarcinoma Advanced, Cholangiocarcinoma Non-resectable, Mesothelin-expressing Advanced Cancers, Mesothelin-positive Advanced Malignant Solid Tumors, Colorectal Cancer

Learn More ›

ivWatch in Prevention of Extravasation of Vesicants in an Oncology Setting

NCT06758011

Recruiting

This study aims to determine the feasibility of using the ivWatch (registered trademark) device to determine if there is an infiltration at the site of a peripheral intravenous (PIV) catheter. An infiltration is when the IV fluid leaks out of a vein and into the surrounding tissue. If medication starts leaking outside the vein, it can cause damage to the surrounding tissue. Using the ivWatch device may identify leaking fluid before the nurse is able to visually observe the signs or symptoms of t... Read More

Gender:

ALL

Ages:

Between 18 years and 95 years

Trial Updated:

07/29/2025

Locations: Roswell Park Comprehensive Cancer Center, Buffalo, New York

Conditions: Oncology, Extravasation

Learn More ›

A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors

NCT06777316

Recruiting

This is an open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4859 in adult participants with intrahepatic cholangiocarcinoma (iCCA) or other advanced solid tumors with FGFR2 and/or FGFR3 genetic alternations.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/29/2025

Locations: Mayo Clinic Scottsdale, Scottsdale, Arizona +14 locations

Conditions: Intrahepatic Cholangiocarcinoma (Icc), Cholangiocarcinoma, Other Solid Tumors, Adult, FGFR2 Gene Fusion/Rearrangement, FGFR2 Gene Amplification, FGFR2 Gene Short Variants, FGFR3 Gene Fusion/Rearrangement, FGFR3 Gene Amplification, FGFR3 Gene Short Variants, FGFR2 Genetic Alterations, FGFR3 Genetic Alterations, Advanced Solid Tumors

Learn More ›